Mobile

A phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunizatio...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003299-40

A phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunization course before 6 months of age

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the immune response to GSK Biologicals’ 10-valent conjugate pneumococcal vaccine one month after the 3rd dose of the primary vaccination course co-administered at 2-3-4 months of age with DTPa-HBV-IPV/Hib.

Critère d'inclusion

  • Three dose vaccination of healthy infants between 8-16 weeks of age at the time of the first vaccination against Streptococcus pneumoniae

Liens